Search This Blog

Monday, June 5, 2017

Amgen Submits Regulatory Applications For Repatha® (evolocumab) Cardiovascular Outcomes Data In US And Europe

Applications Based on Data From Repatha Cardiovascular Outcomes Study Showing an Additional Reduction in Heart Attacks, Strokes and Coronary Revascularizations on Top of Optimized Statin Therapy



Amgen - Investors - RSS Content

No comments:

Post a Comment